FDA Promotes Efficient Biosimilar Approval.

The FDA has approved 12 biosimilar products, including two cancer treatments, yet biosimilars face obstacles in entering the market. The FDA Biosimilars Action Plan outlines steps the agency is taking to facilitate competitiveness of biosimilars, including improving the efficiency of the review process and educating health care professionals about the therapies.